Pfizer sent its first shipment of Retacrit to wholesalers Nov. 12 at a list price of $11.03 per 1,000 units. This is a 33 percent discount on Epogen and a 57 percent discount on Procrit.
Retracrit was approved by the FDA in May 2018 as a red blood cell-producing stimulant.
With the market launch, Pfizer now has three biosimilars available in the U.S.
More articles on pharmacy:
AstraZeneca sells respiratory drug for $1.5B
Express Scripts to launch formulary for lower list price drugs
Nestle pays $98M for increased stake in food allergy drugmaker Aimmune
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
